We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America.
- Authors
Stadler, Walter M.; Figlin, Robert A.; McDermott, David F.; Dutcher, Janice P.; Knox, Jennifer J.; Miller Jr., Wilson H.; Hainsworth, John D.; Henderson, Charles A.; George, Jeffrey R.; Hajdenberg, Julio; Kindwall-Keller, Tamila L.; Ernstoff, Marc S.; Drabkin, Harry A.; Curti, Brendan D.; Chu, Luis; Ryan, Christopher W.; Hotte, Sebastien J.; Xia, Chenghua; Cupit, Lisa; Bukowski, Ronald M.
- Abstract
The article presents a study which reports the safety and efficacy of sorafenib to patients with advanced renal cell carcinoma (ARCC). It states that sorafenib was made available to patients with RCC through the advanced Renal Cell Carcinoma Sorafenib (ARCCS) program. It mentions that the said program was conducted at 319 centers in the U.S. and 8 centers in Canada. Results show that sorafenib is clinically acceptable toxicity profile in patients enrolled in program.
- Subjects
UNITED States; CANADA; DRUG efficacy; CLINICAL drug trials; CANCER treatment; RENAL cell carcinoma; ORAL medicine; DRUG administration
- Publication
Cancer (0008543X), 2010, Vol 116, Issue 5, p1272
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.24864